Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MC4R | P32245 | 1/20 | 0.34 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.34 |
| ▸ | CLPP | Q16740 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2813871 | 0.91 | MRGPRX1 (0.39) | MRGPRX1SRCMAPT | |
| SCHEMBL2812918 | 0.90 | MRGPRX1 (0.38) | GPR84SIGMAR1ALDH1A1MRGPRX1MAPT | |
| SCHEMBL538194 | 0.89 | KMT2A (0.37) | GPR84SIGMAR1ALDH1A1MRGPRX1CLPP | |
| SCHEMBL2811035 | 0.89 | ACHE (0.37) | MRGPRX1CLPPMAPTFFAR1 | |
| SCHEMBL2816649 | 0.88 | MRGPRX1 (0.38) | SIGMAR1MRGPRX1MAPT | |
| SCHEMBL2811115 | 0.87 | MAPT (0.40) | SIGMAR1CLPPMAPTFFAR1FFAR4 | |
| SCHEMBL2816455 | 0.86 | SIGMAR1 (0.34) | GPR84SIGMAR1PRKCQALDH1A1MRGPRX1 | |
| SCHEMBL2808425 | 0.86 | MRGPRX1 (0.39) | SIGMAR1MRGPRX1SLC6A3 | |
| SCHEMBL2810531 | 0.86 | MRGPRX1 (0.48) | MRGPRX1 | |
| SCHEMBL2816668 | 0.85 | MRGPRX1 (0.39) | SIGMAR1ALDH1A1MRGPRX1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8343983-B2 | Substituted pyrazolo-pyrimidine compounds | ARQULE, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20100249110-A1 | SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS | ARQULE, INC. (US) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249110-A1 | SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS | DPYD, TYMP, TP53 | GPR84 3626/4885SIGMAR1 4535/4885PRKCQ 1625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.